We are live on ! Find out more
CLPT icon

ClearPoint Neuro

10.67 USD
-0.02
0.19%
At close Updated Oct 30, 4:00 PM EDT
Pre-market
After hours
10.86
+0.19
1.78%
1 day
-0.19%
5 days
16.36%
1 month
-12.61%
3 months
-26.82%
6 months
-4.56%
Year to date
-23.95%
1 year
-54.94%
5 years
-37.53%
10 years
173.59%
 

About: ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.

Employees: 172

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 4.8%
Neutral 85.7%
Negative 9.5%
Neutral
PRNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
MarketBeat
1 day ago
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call
ClearPoint Neuro NASDAQ: CLPT reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesses. Management said the company is investing in clinical support, laboratory capabilities and product development as it prepares for anticipated cell and gene therapy trial activity and potential commercial launches.
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call
Negative
Zacks Investment Research
1 day ago
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.21 per share a year ago.
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Seeking Alpha
1 day ago
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
Neutral
GlobeNewsWire
3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
PRNewsWire
8 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
GlobeNewsWire
10 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
PRNewsWire
15 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Neutral
Accesswire
16 days ago
ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
SOLANA BEACH, CA / ACCESS Newswire / October 14, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 third quarter on Wednesday, October 28, 2026, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 third quarter on Wednesday, October 28 at 4:30 p.m.
ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
Neutral
GlobeNewsWire
17 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. (“ClearPoint” or the “Company”) (NASDAQ: CLPT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
Price charts implemented using Lightweight Charts™